血清VEGF、Ang-2对非小细胞肺癌诊断特异性及预后判断准确性作用分析

Diagnostic specificity and prognostic judgment accuracy of serum VEGF and Ang-2 on non-small cell lung cancer

目的探讨血清中血管内皮生长因子(VEGF)和血管生成素-2(Ang-2)对非小细胞肺癌(NSCLC)诊断特异性及预后判断的作用。方法选取2011年1月至2014年1月在我院治疗的NSCLC患者178例(病例组),同时选取100例健康者作为对照组,检测血清VEGF和Ang-2含量,分析其与临床病理、预后的关系。结果病例组VEGF和Ang-2分别为(553.21±78.43)pg/mL和(390.12±90.70)pg/mL,明显高于对照组(P<0.05);NSCLC患者VEGF和Ang-2与患者年龄、性别及病理类型无关(P>0.05);伴淋巴结转移患者VEGF和Ang-2明显高于无淋巴结转移患者(P<0.05);临床分期为Ⅲ-Ⅳ期患者VEGF和Ang-2明显高于Ⅰ-Ⅱ期患者(P<0.05);VEGF高水平患者生存时间为(18.97±0.95)月,明显低于VEGF低水平患者的(23.80±0.82)月(P<0.05);Ang-2高水平患者生存时间为(19.42±0.91)月,明显低于Ang-2低水平患者的(23.71±0.81)月(P<0.05);VEGF曲线下面积为0.907,截断值为442.45pg/mL,灵敏度为91.60%,特异度为89.00%;Ang-2曲线下面积为0.802,截断值为312.43pg/mL,灵敏度为82.60%,特异度为85.00%。结论血清VEGF和Ang-2可作为NSCLC诊断以及预后判断的分子标志物,具有重要的临床应用价值。

Objective To investigate the diagnostic specificity and prognostic judgment accuracy of serum VEGF and Ang-2 on non-small cell lung cancer （NSCLC）. Methods From January 2011 and January 2011 in our hospital, 178 patients with NSCLC were selected as the case group, and 100 healthy people were taken as the control group. It used ELISA to detect serum VEGF and Ang-2 content to analyze its relationship with clinical pathology and prognosis. Results The levels of VEGF and Ang-2 were （553. 21 ±78. 43） pg/mL and （390. 12 ± 90. 70） pg/ mL in the case group, which were significantly higher than those in the control group （ P 〈 0. 05 ） . The level of VEGF and Ang-2 had nothing to do with their age, gender and pathological type （ P 〉 0. 05 ） , but it was obviously higher in patients with lymph node metastasis than in patients without lymph node metastasis （P 〈 0. 05 ） . It was significantly higher in patients at clinical stage Ⅲ - Ⅳ than in patients at stage Ⅰ - Ⅱ （ P 〈 0. 05 ） . The level of VEGF was significantly higher in patients with survival time of （ 18. 97 ± 0. 95 ） months than in patients with （ 23. 80 ± 0. 82 ） months survival time （P 〈0. 05）,and the level of Ang-2 was higher in patients with （ 19. 42 ±0. 91） months survival time than in patients with （23. 71 ±0. 81） months （P 〈0. 05 ）. For VEGF, the area under the curve of VEGF was 0. 907, the cut-off value was 442. 45 pg/mL, the sensitivity was 91. 60% , and the specificity was 89. 00% . For Ang-2, the area under the curve was 0. 802, the cut-off value was 312. 43 pg/mL, the sensitivity was 82. 60% , and the specificity was 85. 00% . Conclusion Serum VEGF and Ang-2 can be used as molecular markers in NSCLC diagnosis and prognosis judgment, which has important clinical value.